Charts for Quick CASH $$$ Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Charts for Quick CASH $$$

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Galirayo who wrote (5350)	12/11/1997 2:24:00 AM
From: John Metcalf	Read Replies (1) of 9262

NeoPharm (NEO-AMEX) had a big day, up 43%. The mainstream press has picked up news on a promising anti-cancer agent that they licensed from Natl Inst of Health. It's a little controversial because the public paid for development of the product and also because there is some opposition to NIH doing drug discovery, when private industry can do it. The compound is something complexed to IL13, which binds to various cancerous cells and destroys them. It is _very early_ in development. NEO also has a cancer diagnostic product, Neomark (broxuridine for injection), for use as a cell proliferation marker to determine the labeling index in breast cancer. The FDA's Oncologic Drug Advisory Cmte will hold a hearing on it December 19. That's a lot of possibility for an unknown $60mm company. Disclaimer: I haven't researched this properly; just telling you the news, since you asked.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next